Patents by Inventor Karsten Kristiansen
Karsten Kristiansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240148798Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.Type: ApplicationFiled: January 16, 2024Publication date: May 9, 2024Applicants: Norges Miljo-Og BIovitenskapelige Universitet (NMBU), Sykehuset Ostfold HF, University of CopenhagenInventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
-
Patent number: 11911418Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.Type: GrantFiled: April 12, 2022Date of Patent: February 27, 2024Assignees: Norges Miljo-Og Blovitenskapelige Universitet (NMBU), Sykehuset Ostfold HF, University of CopenhagenInventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
-
Publication number: 20220305062Abstract: Described is a method for the treatment or prevention of GI tract dysbiosis in a subject, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method including administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.Type: ApplicationFiled: April 12, 2022Publication date: September 29, 2022Inventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
-
Patent number: 11331349Abstract: The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.Type: GrantFiled: August 2, 2018Date of Patent: May 17, 2022Assignees: NORGES MILJO-OG BIOVITENSKAPELIGE UNIVERSITET (NMBU), SYKEHUSET OSTFOLD HF, UNIVERSITY OF COPENHAGENInventors: Tor Lea, Charlotte Kleiveland, Karsten Kristiansen, Benjamin Anderschou Holbech Jensen, Jacob Bak Holm, Ida Sogaard Larsen, Morten Jacobsen
-
Publication number: 20200368292Abstract: The invention provides a method for the treatment or prevention of GI tract dysbiosis in a subject, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. The invention further provides a method for the treatment or prevention of a disease or condition selected from small intestine bacterial overgrowth (SIBO), small intestine fungal overgrowth syndrome (SIFO), GI tract cancers, breast cancer, neurological disorders, malnutrition, chronic fatigue syndrome, autism, cardiovascular diseases and GI tract infections in a subject with GI tract dysbiosis, said method comprising administering an effective amount of a non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus to said subject. A non-viable Methylococcus capsulatus or a lysate of Methylococcus capsulatus for use in said methods is further provided.Type: ApplicationFiled: August 2, 2018Publication date: November 26, 2020Inventors: TOR LEA, CHARLOTTE KLEIVELAND, KARSTEN KRISTIANSEN, BENJAMIN ANDERSCHOU HOLBECH JENSEN
-
Publication number: 20140288110Abstract: 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections.Type: ApplicationFiled: March 24, 2014Publication date: September 25, 2014Applicant: EVOLVA SAInventors: Karsten KRISTIANSEN, Prathama S. MAINKAR, Jean-Philippe MEYER, Alexandra Santana SORENSEN
-
Publication number: 20110265192Abstract: A sensor system for detecting the activation of specific nuclear receptors in a tissue of an animal is provided. The nuclear receptor sensor system comprises a sensor component comprising a nuclear receptor or part thereof coupled to a DNA-binding domain, and a reporter component comprising a reporter gene. Transgenic animals, such as a transgenic pig is provided, which comprises the components of the nuclear receptor sensor system in its genome. Also methods of producing the transgenic animal is provided as well as use of the transgenic animal for evaluating the activity of a nuclear receptor in vivo.Type: ApplicationFiled: September 3, 2009Publication date: October 27, 2011Applicants: SYDDANSK UNIVERSITET, AARHUS UNIVERSITETInventors: Lars Axel Bolund, Karsten Kristiansen, Jacob Giehm Mikkelsen, Nicklas Heine Staunstrup
-
Publication number: 20110178112Abstract: 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections.Type: ApplicationFiled: January 18, 2007Publication date: July 21, 2011Applicant: EVOLVA SAInventors: Karsten Kristiansen, Prathama S. Mainkar, Jean-Philippe Meyer, Alexandra Santana Sorensen
-
Publication number: 20100122356Abstract: The present invention relates to a genetically modified pig as a model for studying psoriasis. The modified pig model displays one or more phenotypes associated with psoriasis. Disclosed is also a modified pig comprising a mutation in the endogenous ILK-I Ra, JunB/cJun, CD18, IKK2, and/or LIG1 gene, and/or a human, porcine and/or murine PPARs, PPAR-?, l?B-?, STAT3c, Integrin beta 1, Integrin alpha 2, MEK1, Amphiregulin, BMP-6, VEGF, JunB?ec-Jun?ep, IL-I a, TGF.beta 1, CD18 hypo, Cre/lkk2FL/FL, Dsg1, SCCE, TGF-a, TNF-a, IL-20, IFN-g, LIG1 KO, KGF, IL-6, PAFR1 Cre/lkk2FL/FL, IL1 R, Dsg3, IFN-gamma, p40, ILI Ra, IKK2, JunB/c-Jun, and/or LIG1 gene, transcriptional and/or translational product or part thereof. The invention further relates to methods for producing the modified pig; and methods for evaluating the effect of a therapeutical treatment of psoriasis, for screening the efficacy of a pharmaceutical composition, and a method for treatment of human being suffering from psoriasis are disclosed.Type: ApplicationFiled: March 7, 2008Publication date: May 13, 2010Applicants: AARHUS UNIVERSITET, LEO PHARMA A/S, SYDDANSK UNIVERSITETInventors: Peter Michael Kragh, Lars Axel Bolund, Karsten Kristiansen, Charlotte Brandt Sørensen, Jacob Giehm Mikkelsen, Nicklas Heine Staunstrup, Thomas Kongstad Petersen, Lars Svensson
-
Patent number: 7230029Abstract: The present invention relates to fatty acid analogues of the general formula (I): R1-[xi-CH2]n—COOR2 wherein R1 is; a C1–C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C1–C24 alkyne, and/or a C1–C24 alkyl, or a C1–C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1–C4 alkoxy, C2–C4 alkylthio, C1–C5 acyloxy or C1–C4 alkyl, and wherein R2 represents hydrogen or C1–C4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, and with the proviso that if R1 is an alkyne or alkene, then the carbon-carbon triple bond or double bond is positioned between the (?-1) carbon and the (?-2) carbon, or between the (?-2) carbon and the (?-3) carbon, or between tType: GrantFiled: September 27, 2001Date of Patent: June 12, 2007Assignee: Thia Medica ASInventors: Rolf Berge, Karsten Kristiansen
-
Publication number: 20040019108Abstract: The present invention relates to fatty acid analogues of the general formula (I): R1-[xi-CH2]n—COOR2 wherein R1 is; a C1-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C1-C24 alkyne, and/or a C1-C24 alkyl, or a C1-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C2-C4 alkylthio, C1-C5 acyloxy or C1-C4 alkyl, and wherein R2 represents hydrogen or C1-C4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, and with the proviso that if R1 is an alkyne or alkene, then the carbon-carbon triple bond or double bond is positioned between the (&ohgr;-1) carbon and the (&ohgr;-2) carbon, or between the (&ohgr;-2) carbon andType: ApplicationFiled: May 8, 2003Publication date: January 29, 2004Inventors: Rolf Berge, Karsten Kristiansen